A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid.
about
Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung functionInflammatory cytokines induce production of CHI3L1 by articular chondrocytesYKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitisThe chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathwaysPotential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cellsEarly and stable upregulation of collagen type II, collagen type I and YKL40 expression levels in cartilage during early experimental osteoarthritis occurs independent of joint location and histological grading.Perspectives for Monocyte/Macrophage-Based Diagnostics of Chronic InflammationCrystal structure of a novel regulatory 40-kDa mammary gland protein (MGP-40) secreted during involutionCrystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39Structure of the buffalo secretory signalling glycoprotein at 2.8 Å resolutionBiochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein familyHigh serum YKL-40 level after surgery for colorectal carcinoma is related to short survivalRole of breast regression protein-39/YKL-40 in asthma and allergic responsesThe immunologic homunculus in rheumatoid arthritis.Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinomaHuman cartilage glycoprotein 39--biomarker of joint damage in knee osteoarthritis.YKL-40 as a novel factor associated with inflammation and catabolic mechanisms in osteoarthritic jointsProgress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis.The chitinase and chitinase-like proteins: a review of genetic and functional studies in asthma and immune-mediated diseases.Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.Serum levels of YKL-40 and C reactive protein in patients with hip osteoarthritis and healthy subjects: a cross sectional study.Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions.Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis.Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort.Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.Cells from the skin of patients with systemic sclerosis secrete chitinase 3-like protein 1.Serum YKL-40 and colorectal cancer.Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review.Is YKL-40 a new therapeutic target in cancer?Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis.Human chitinases and chitinase-like proteins as indicators for inflammation and cancerYKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?Quantitative proteomics reveals regulatory differences in the chondrocyte secretome from human medial and lateral femoral condyles in osteoarthritic patientsYKL-40: a potential biomarker for osteoarthritis.Plasma YKL-40: a potential new cancer biomarker?CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors.Application of biochemical markers in development of drugs for treatment of osteoarthritis.Breast regression protein-39 (BRP-39) promotes dendritic cell maturation in vitro and enhances Th2 inflammation in murine model of asthma.YKL-40: a new biomarker in cardiovascular disease?
P2860
Q24319020-0125AF84-1FB7-46EB-9CD3-2A110117BC08Q24338555-E84EFD16-47F9-4A72-9A0E-5162AAEA7315Q24531928-4411D964-4942-4A12-A9BD-C29FA2ECEC7EQ24534189-334EE057-8886-4A56-BC1A-05CA31A7402CQ24656942-5ECF56DB-3324-4B2A-B994-8B5F26C2FD5CQ24799322-D0B6FA71-CFED-49B5-A31B-95C6475FF234Q26745913-32B6E8D9-D606-4BF8-B274-49C8EB8DC966Q27640320-00EA4366-AD29-4D2E-A3E7-9DC5AD92C264Q27641650-9E4D3521-3B5C-4758-ABBE-65555660D484Q27644311-C6E85626-F587-4919-B6FD-01060EB5C807Q27687777-DC79EE46-8588-436D-8EE9-7FB17F8A9897Q28114774-0646C0CE-2FEA-4C05-A812-5E8FC553016AQ28215091-C8100BCE-CBA6-4792-8990-86229054AFCBQ33701312-296AAE36-FDA7-4625-92D7-86B6C20E3A3AQ33806414-DA0C2090-635E-471F-879B-CAA16639ABABQ33891544-F670DC5B-EC44-434D-B683-DE88F88A4631Q33969785-2A4EFC26-D65D-4527-B790-30E1FD5BAC58Q34012380-693A09B0-61C4-4F1C-B619-7AF959600EEDQ34118568-55F63725-37FB-4ADE-A332-F415787138D3Q34479904-B429B80A-D816-4021-B4E3-AF12E8DDFDF9Q34605692-0ED6D939-F651-45B4-A8DE-FD101B89A41FQ35548928-9943646D-4C56-4F3D-8906-64A8244813C0Q35549462-1AE69D2E-6936-4EEB-9383-D7679EA0E797Q35549775-4D6DC7DE-AAD1-4BE5-B119-708E094227D5Q35636920-430AA341-E4A0-4D57-967B-48039A1A72AEQ35647254-3D78E9FF-7371-42B4-8A68-198B062F38FCQ36250788-A3B54127-DE86-44DA-917F-944A780FCBB2Q36619099-831DD4A5-51B8-40D5-B03C-25D704756F1EQ36631211-0A6DEDDA-AB48-41C7-AC01-CC4243B0DED1Q36709555-D54980CC-1B90-453F-9777-11881C5CE451Q37273123-2E0CF78A-F8AA-47FE-AE2E-400743816F36Q37280948-6CC8D84D-6232-46B4-AF3B-F53C949705CFQ37334247-ABD2366E-C2E3-4D55-8C56-051A99F0CD6AQ37364390-0AD45CBA-1F80-4888-85D3-023028926AF6Q37392423-B1875C2B-D640-4298-AA55-74FFF02BC8C0Q37605869-F93A469D-2960-4D0D-9D63-AC4A23786A16Q37665099-3BC55D26-3248-4C16-89CA-33C456AA67D7Q37677789-E9A5C5E3-9DCC-4CFF-BB27-33AFD93AFD0EQ37727177-017FF121-346E-4AD7-AC42-07984038C9F9Q37779310-DA6501A2-A4B9-4EA6-A8EE-EB3E36BFB5AA
P2860
A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
A new biochemical marker for j ...... 0 in serum and synovial fluid.
@en
type
label
A new biochemical marker for j ...... 0 in serum and synovial fluid.
@en
prefLabel
A new biochemical marker for j ...... 0 in serum and synovial fluid.
@en
P356
P1476
A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid
@en
P2093
J S Johansen
P304
P356
10.1093/RHEUMATOLOGY/32.11.949
P577
1993-11-01T00:00:00Z